Dag Sehlin, PhD, is an Associate Professor of Neurobiology at Uppsala University. His research focuses on Alzheimer’s disease, developing therapeutic and diagnostic tools, including engineered antibodies targeting amyloid-betaDag has played an important role in the research behind the development of Lecanemab, an amyloid-beta antibody recently approved for Alzheimer's treatment by both the FDA in the U.S. and the EMA in Europe.Episode timestamps:00:00 - Guest Introduction: Dag Sehlin, Associate Professor of Neurobiology 03:25 - Progression of Alzheimer's Disease in the Brain 05:48 - Comorbidities and Challenges in Diagnosing Alzheimer's 12:54 - Tau and Amyloid Beta Markers in Cerebrospinal Fluid 17:00 - Future Potential of Blood Tau for Early Alzheimer's Detection 24:01 - FDA & EMA Approval of Lecanemab for Alzheimer's Treatment 25:27 - Lecanemab: First Disease-Modifying Alzheimer's Treatment 35:23 - Clinical Benefits of Lecanemab Beyond Cognitive Function (Quality of Life, Hospitalization Rates and More) 58:39 - Dose-Dependent Side Effects and Future Improvements 01:00:54 - Transferrin Receptor "Trojan Horse" Mechanism for Blood-Brain Barrier Penetration 01:15:16 - Neuroinflammation: Beneficial vs. Harmful Effects and Possible Solutions01:39:37 - AI and Brain Imaging: Enhancing Precision01:42:04 - Enhancing Collaboration Between Academia and Big Pharma Companies

Ver todos los episodios